SPRYCEL |
DASATINIB |
BMS-354825 HYDRATE |
BMS-354825 |
DASATINIB HYDRATE |
BMS-354825-03 |
DASATINIB MONOHYDRATE |
BMS 345825 |
BMS 35482513 |
ANHYDROUS DASATINIB |
BMS 354825 |
SPRYCEL® |
ANH. DASATINIB |
DASATINIB ANHYDROUS |
DASATINIB (ANH.) |
chemidplus:302962-49-8 |
drugbank:01254 |
pubchem.compound:3062316 |
chembl:CHEMBL1421 |
rxcui:1546019 |
Year of Approval | 2006 |
Drug Class | antineoplastic agents, protein kinase inhibitors |
FDA Approval | Chronic myelogenous leukemia (Philadelphia chromosome positive), Acute lymphoblastic leukemia (Ph +) |
Drug Class | Kinase Inhibitors |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Source Reported Drug Name(s) | Dasatinib/Sprycel/ BMS-354825 |
Pharmaceutical Developer | Bristol-Myers Squibb |
Source Reported Drug Name(s) | Dasatinib |
Drug Class | Kit Inhibitor |
inhibitor (inhibitory) |
Trial Name | dasatinib, BMS-354825,Sprycel |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Pathway | activation |
Variant Effect | gain-of-function |
multitarget |
inhibitor (inhibitory) |
Trial Name | dasatinib, BMS-354825,Sprycel |
Novel drug target | Established target |
Clinical Status | NCCN guidelines |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
Clinical Status | preclinical |
Clinical Status | early trials |
multitarget |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | SRC inhibitor |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | SRC inhibitor |
Direct Interaction | yes |
n/a |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | preclinical |
inhibitor (inhibitory) |
Mechanism of Interaction | SRC inhibitor |
Direct Interaction | yes |
multitarget |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | dasatinib, BMS-354825,Sprycel |
Mechanism of Interaction | SRC inhibitor |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Variant Effect | reduced kinase activity |
Pathway | activation |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor beta inhibitor |
Trial Name | dasatinib, BMS-354825,Sprycel |
multitarget |
inhibitor (inhibitory) |
Trial Name | dasatinib, BMS-354825,Sprycel |
Novel drug target | Established target |
Mechanism of Interaction | SRC inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | SRC inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | SRC inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | SRC inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | dasatinib, BMS-354825,Sprycel |
Novel drug target | Established target |
Mechanism of Interaction | SRC inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | SRC inhibitor |
inhibitor (inhibitory) |
Notes |
3062316 | PubChem Drug ID |
Sprycel | Drug Trade Name |
Sprycel | Drug Development Name |
Drug Class | Kit Inhibitor |
Source Reported Drug Name(s) | Dasatinib |
Pharmaceutical Developer | Bristol-Myers Squibb |
BMS-354825 | Development Name |
SPRYCEL | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Chronic myelogenous leukemia (Philadelphia chromosome positive), Acute lymphoblastic leukemia (Ph +) |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Year of Approval | 2006 |
CHEMBL1421 | ChEMBL Drug ID |
SPRYCEL | Drug Trade Name |
BMS-354825 | Drug Synonym |
D0E6XR | TTD Drug ID |